US 12083098
Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors
granted A61KA61K31/404A61K31/407
Quick answer
US patent 12083098 (Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors) held by ACTUATE THERAPEUTICS INC. expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ACTUATE THERAPEUTICS INC.
- Grant date
- Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/404, A61K31/407, A61K9/0073, A61P